RxDoctor Payments Data

Bharat Tolia, MD

Neurology · Bloomfield Hills, MINPI 1770535171

Payments from drug & device makers

$16,254in general payments, 2019–2025

Across 744 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • SK Life Science, Inc.$2K
  • Livanova USA, Inc.$2K
  • Eisai Inc.$1K
  • Sunovion Pharmaceuticals Inc.$936
  • Harmony Biosciences LLC$866
  • plus $6K from 39 others

What the payments were for

  • Consulting fees$2,35014%
  • Speaking & faculty fees$590%
  • Travel & lodging$1,3548%
  • Food & beverage$12,27276%
  • Education$2181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,254 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$52,724
Medicare patients
31
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate79$92,939
AptiomEslicarbazepine Acetate44$78,773
GlatopaGlatiramer Acetate13$38,011
FycompaPerampanel32$35,489
BriviactBrivaracetam19$25,758
Rufinamide25$11,192
Adderall XrDextroamphetamine/Amphetamine11$5,361
Lurasidone Hcl36$3,136
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine141$2,982
Lacosamide27$2,769
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone12$2,068
Gabapentin165$1,798
Levetiracetam65$1,689
Tizanidine Hcl53$1,678
Tolterodine Tartrate ErTolterodine Tartrate18$1,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$2,207$92,93979 claims
Sunovion Pharmaceuticals Inc.Aptiom$936$78,77344 claims
Eisai Inc.Fycompa$1,105$35,48932 claims
UCB, Inc.Briviact$275$25,75819 claims
Upsher-smith Laboratories LLCTopiramate$19$98495 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 652 neurology providers in Michigan.

Other neurology in Bloomfield Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →